Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 1.00 |
| ▸ | CA2 | P00918 | 4/20 | 1.00 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.59 |
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
| ▸ | CA6 | P23280 | 1/20 | 0.59 |
| ▸ | CA5A | P35218 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.59 |
| ▸ | LTA4H | P09960 | 5/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.56 |
| ▸ | BAX | Q07812 | 1/20 | 0.56 |
| ▸ | MGLL | Q99685 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Magnesium Chloride Anhydrous SCHEMBL20694917 | 0.92 | CA1 (0.84) | CA1CA2ENPP2CA4CA6 | |
| SCHEMBL6001606 | 0.90 | CA2 (0.81) | CA1CA2ENPP2CA4CA6 | |
| SCHEMBL16151490 | 0.86 | CA1 (0.75) | CA1CA2LTA4HTSHRNR1H2 | |
| SCHEMBL8437226 | 0.84 | CA1 (0.71) | CA1CA2ENPP2CA4CA6 | |
| SCHEMBL10269840 | 0.84 | CA1 (0.72) | CA1CA2ENPP2CA4CA6 | |
| SCHEMBL3787238 | 0.82 | CA1 (0.69) | CA1CA2ENPP2CA4CA6 | |
| Diphenylether SCHEMBL787081 | 0.82 | LTA4H (0.75) | CA1CA2LTA4HTSHRNR1H2 | |
| SCHEMBL14165789 | 0.81 | ENPP2 (0.71) | CA1CA2ENPP2LTA4HNR1H2 | |
| SCHEMBL31563612 | 0.80 | CA1 (0.67) | CA1CA2ENPP2CA4CA6 | |
| SCHEMBL257834 | 0.80 | CA1 (0.67) | CA1CA2ENPP2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1633 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | claimed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | claimed |
| US-20250101021-A1 | METHODS OF MAKING TOLEBRUTINIB | PRINCIPIA BIOPHARMA INC. (US) | 2025-03-27 | — | — | US | claimed |
| CN-119390717-A | Preparation method of 4-phenoxyphenylboronic acid | 安徽英特美科技有限公司 | 2025-02-07 | — | — | CN | claimed |
| CN-119384411-A | Method for preparing tolmetinib | 普林斯匹亚生物制药公司 | 2025-01-28 | — | — | CN | claimed |
| CN-118344321-A | Gamma-pyrone derivative and synthetic method and application thereof | 武汉轻工大学 | 2024-07-16 | — | — | CN | claimed |
| CN-118255693-A | Biphenyl compound and application thereof in preparation of medicines for treating leukemia, lung cancer and breast cancer | 大连理工大学 | 2024-06-28 | — | — | CN | claimed |
| CN-115572297-B | Pyrazolopyrimidine-containing o-phenylenediamine derivative, and preparation method and application thereof | 山东大学 | 2024-04-26 | — | — | CN | claimed |
| WO-2024016826-A1 | 6-POSITION SUBSTITUTED DIHYDROBENZO[E][1,2,3]OXATHIAZINE 2,2-DIOXIDE COMPOUND, PREPARATION THEREFOR, AND USE THEREOF | 杭州市第七人民医院 | 2024-01-25 | — | — | WO | claimed |
| WO-2023244587-A1 | METHODS OF MAKING TOLEBRUTINIB | GENZYME CORPORATION (US) | 2023-12-21 | — | — | WO | claimed |
| WO-2017017619-A1 | PROCESS FOR THE PREPARATION OF IBRUTINIB AND NEW SYNTHESIS INTERMEDIATE | OLON S.P.A. (IT) | 2017-02-02 | — | — | WO | claimed |
| WO-2016132383-A1 | PROCESS FOR THE PREPARATION OF IBRUTINIB | MYLAN LABORATORIES LIMITED (IN) | 2016-08-25 | — | — | WO | claimed |
| US-9340575-B2 | Agonists and antagonists of the urotensinergic system | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2016-05-17 | — | — | US | claimed |
| EP-2729184-A1 | NOVEL AGONISTS AND ANTAGONISTS OF THE UROTENSINERGIC SYSTEM | Institut National de la Recherche Scientifique (CA) | 2014-05-14 | — | — | EP | claimed |
| US-20140113872-A1 | NOVEL AGONISTS AND ANTAGONISTS OF THE UROTENSINERGIC SYSTEM | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2014-04-24 | — | — | US | claimed |
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| WO-2012149644-A1 | NOVEL AGONISTS AND ANTAGONISTS OF THE UROTENSINERGIC SYSTEM | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2012-11-08 | — | — | WO | claimed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | claimed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113872-A1 | NOVEL AGONISTS AND ANTAGONISTS OF THE UROTENSINERGIC SYSTEM | UTS2R, SCTR, PLAUR | CA1 4204/4885CA2 3993/4885ENPP2 205/4885 |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | GFER, MUC1, CTH | CA1 1918/4885CA2 2856/4885ENPP2 854/4885 |
| US-20250101021-A1 | METHODS OF MAKING TOLEBRUTINIB | ABL1, JAK2, JAK1 | CA1 4884/4885CA2 4757/4885ENPP2 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.